Applicability and Cost Implications for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Based on the ODYSSEY Outcomes Trial: Insights From the Department of Veterans Affairs

Salim S. Virani, Julia M. Akeroyd, Vijay Nambi, Erin D. Michos, Pamela B. Morris, Khurram Nasir, Sidney C. Smith, Neil J. Stone, Laura A. Petersen, Christie M. Ballantyne

Research output: Contribution to journalLetterpeer-review

Original languageEnglish (US)
Pages (from-to)410-412
Number of pages3
JournalCirculation
Volume139
Issue number3
DOIs
StatePublished - Jan 15 2019

Keywords

  • cholesterol
  • clinical trial

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Cite this